ClinicalTrials.gg
CompletedNCT07813897Updated Sep 10, 2026

Efficacy of Palonosetron Plus Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Gynaecological Laparoscopic Surgery

A Phase 4 interventional study of Palonosetron and Dexamethason and Palonosetron in Postoperative Nausea and Vomiting, sponsored by Bangladesh Medical University. Completed at 1 site in Bangladesh. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Bangladesh Medical University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2025, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Postoperative nausea and vomiting (PONV) is a common complication after general anaesthesia, especially among female patients undergoing laparoscopic surgery. This randomized controlled trial evaluates whether combined palonosetron and dexamethasone is more effective than palonosetron alone in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.

Eligible patients will be randomized into two parallel groups. The intervention group will receive palonosetron plus dexamethasone, while the comparator group will receive palonosetron alone. Patients will be followed for 24 hours after surgery for incidence and severity of nausea and vomiting, rescue antiemetic requirement, adverse effects, patient satisfaction, and haemodynamic parameters.

Read the detailed description

Postoperative nausea and vomiting (PONV) is a common and distressing complication following general anaesthesia, particularly among female patients undergoing laparoscopic surgical procedures. Although several medications are available for prevention of PONV, no single agent completely eliminates the risk because multiple physiological and surgical factors contribute to its development.

Palonosetron is a second-generation serotonin (5-hydroxytryptamine-3 or 5-HT3) receptor antagonist with a prolonged duration of action and strong receptor affinity. It reduces nausea and vomiting by blocking serotonin-mediated pathways involved in the vomiting reflex. Dexamethasone, a corticosteroid with antiemetic properties, has also been shown to enhance the effectiveness of other antiemetic medications through multiple mechanisms, including modulation of inflammatory pathways and enhancement of antiemetic receptor sensitivity.

This randomized controlled trial is designed to evaluate whether adding dexamethasone to palonosetron provides improved prevention of postoperative nausea and vomiting compared with palonosetron alone in patients undergoing gynaecological laparoscopic surgery under general anaesthesia.

Participants will be randomly assigned to receive either combined palonosetron and dexamethasone or palonosetron alone before induction of anaesthesia. All participants will undergo standardized anaesthetic management and postoperative monitoring. The study will assess the effectiveness and safety of these preventive strategies during the postoperative period.

The findings of this study may provide additional evidence regarding the role of combination antiemetic therapy in improving postoperative recovery, patient comfort, and satisfaction after laparoscopic gynaecological procedures. The results may contribute to optimizing perioperative care practices and improving the management of patients at risk of postoperative nausea and vomiting.

02

Conditions studied

  • Postoperative Nausea and Vomiting

Keywords

  • Postoperative nausea vomiting
  • Efficacy
  • Palanosetron
  • Dexamethason
  • Gynaecological laparoscopic surgery
03

In context

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

This study's enrollment of 76 is below the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.

Browse Postoperative Nausea and Vomiting studies →

Lead sponsor

Bangladesh Medical University is the lead sponsor of 45 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing gynaecological laparoscopic surgery
  • I and II
  • Age 20-40 years
  • Provided

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Menstruation
  • Gastroesophageal reflux disease
  • >35 kg/m²
  • Allergy or to study drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Palonosetron and Dexamethasone

    Participants receive palonosetron 0.075 mg IV combined with dexamethasone 5 mg IV before induction of general anaesthesia.

    Drug: Palonosetron and Dexamethason

  • Active comparator
    .Palanosetron alone

    Participants receive palonosetron 0.075 mg IV before induction of general anaesthesia

    Drug: Palonosetron

Interventions

  • DrugPalonosetron and Dexamethason

    Participants receive palonosetron 0.075 mg IV combined with dexamethasone 5 mg IV before induction of general anaesthesia.

  • Participants receive palonosetron 0.075 mg IV before induction of general anaesthesia.

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative nausea and vomiting

    Occurrence of nausea and vomiting episodes during the postoperative period (0-24 hours).

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Severity of postoperative nausea and vomiting

    Severity of nausea and vomiting will be assessed using the Visual Analogue Scale (VAS), where 0 indicates no nausea and 10 indicates the worst possible nausea. The severity will be evaluated and compared between the two study groups during the postoperative period.

    Time frame: 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours after surgery

  2. Requirement of rescue antiemetic medication

    The requirement for rescue antiemetic medication will be recorded and compared between groups. Patients experiencing significant nausea or vomiting (VAS score ≥4) will receive rescue antiemetic treatment with intravenous metoclopramide 10 mg, and the total requirement will be documented.

    Time frame: During the first 24 hours after surgery

  3. Incidence of adverse effects related to study drugs

    Drug-related adverse effects, including dizziness, headache, and arrhythmia, will be monitored and compared between the study groups using a four-point severity scale.

    Time frame: During the first 24 hours after surgery

  4. Patient satisfaction after surgery

    Patient satisfaction regarding postoperative recovery and nausea-vomiting management will be assessed using a 5-point Likert satisfaction scale, where 1 indicates very dissatisfied, and 5 indicates very satisfied. Higher scores indicate greater patient satisfaction. The satisfaction scores will be compared between the two study groups.

    Time frame: At 24 hours after surgery

  5. Postoperative systolic blood pressure (SBP)

    Systolic blood pressure will be measured and compared between the palonosetron-dexamethasone group and the palonosetron alone group during the postoperative period.

    Time frame: At 1, 6, 12, and 24 hours after surgery

  6. Postoperative diastolic blood pressure (DBP)

    Diastolic blood pressure will be measured and compared between the study groups during postoperative follow-up.

    Time frame: At 1, 6, 12, and 24 hours after surgery

  7. Postoperative mean arterial pressure (MAP)

    Mean arterial pressure will be recorded and compared between the two study groups during the postoperative period.

    Time frame: At 1, 6, 12, and 24 hours after surgery

  8. Postoperative heart rate (HR)

    Heart rate will be monitored and compared between the palonosetron-dexamethasone group and the palonosetron alone group after surgery.

    Time frame: At 1, 6, 12, and 24 hours after surgery

  9. Postoperative oxygen saturation (SpO₂)

    Peripheral oxygen saturation (SpO₂) will be measured using pulse oximetry and compared between the two study groups during postoperative follow-up.

    Time frame: At 1, 6, 12, and 24 hours after surgery

07

Study locations

1 site
  • Bangladesh Medical University
    Dhaka, 100, Bangladesh
08

References and documents

Publications

  • Cho E, Kim DH, Shin S, Kim SH, Oh YJ, Choi YS. Efficacy of Palonosetron-Dexamethasone Combination Versus Palonosetron Alone for Preventing Nausea and Vomiting Related to Opioid-Based Analgesia: A Prospective, Randomized, Double-blind Trial. Int J Med Sci. 2018 Jun 13;15(10):961-968. doi: 10.7150/ijms.24230. eCollection 2018. PubMed 30013436 ↗
  • Minkowitz H, Leiman D, Lu L, Reines S, Ryan M, Harnett M, Singla N. IV Tramadol - A New Treatment Option for Management of Post-Operative Pain in the US: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery. J Pain Res. 2020 May 22;13:1155-1162. doi: 10.2147/JPR.S251175. eCollection 2020. PubMed 32547178 ↗
  • Ryoo SH, Yoo JH, Kim MG, Lee KH, Kim SI. The effect of combination treatment using palonosetron and dexamethasone for the prevention of postoperative nausea and vomiting versus dexamethasone alone in women receiving intravenous patient-controlled analgesia. Korean J Anesthesiol. 2015 Jun;68(3):267-73. doi: 10.4097/kjae.2015.68.3.267. Epub 2015 May 28. PubMed 26045930 ↗
  • Bala I, Bharti N, Murugesan S, Gupta R. Comparison of palonosetron with palonosetron-dexamethasone combination for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Minerva Anestesiol. 2014 Jul;80(7):779-84. Epub 2013 Nov 26. PubMed 24280811 ↗
  • Ho CM, Wu HL, Ho ST, Wang JJ. Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk. Acta Anaesthesiol Taiwan. 2011 Sep;49(3):100-4. doi: 10.1016/j.aat.2011.06.002. PubMed 21982171 ↗
  • Park SK, Cho EJ. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery. J Int Med Res. 2011;39(2):399-407. doi: 10.1177/147323001103900207. PubMed 21672343 ↗
  • Laha B, Hazra A, Mallick S. Evaluation of antiemetic effect of intravenous palonosetron versus intravenous ondansetron in laparoscopic cholecystectomy: a randomized controlled trial. Indian J Pharmacol. 2013 Jan-Feb;45(1):24-9. doi: 10.4103/0253-7613.106430. PubMed 23543732 ↗
  • Balyan R, Kumar S, Lalitha K, Aneja S, George J. A Randomised Study To Compare Palonosetron With Ondansetron for Prophylaxis of Postoperative Nausea and Vomiting (PONV) Following Laparoscopic Gynecological Surgeries. Cureus. 2022 Mar 29;14(3):e23615. doi: 10.7759/cureus.23615. eCollection 2022 Mar. PubMed 35505760 ↗
  • Kim SH, Hong JY, Kim WO, Kil HK, Karm MH, Hwang JH. Palonosetron has superior prophylactic antiemetic efficacy compared with ondansetron or ramosetron in high-risk patients undergoing laparoscopic surgery: a prospective, randomized, double-blinded study. Korean J Anesthesiol. 2013 Jun;64(6):517-23. doi: 10.4097/kjae.2013.64.6.517. Epub 2013 Jun 24. PubMed 23814652 ↗
  • Xu H, Rong L, Yang S, Xing J, Dong H, Liu H, Chen X, Liu L. 5-HT3 receptor antagonists for preventing postoperative nausea and vomiting after gynecological surgery: A systematic review and network meta-analysis. Int J Gynaecol Obstet. 2025 Oct;171(1):177-189. doi: 10.1002/ijgo.70197. Epub 2025 May 9. PubMed 40348596 ↗
  • Reddy GS, Manjusruthi B, Jyothsna G. Postoperative Nausea and Vomiting Prophylaxis: A Comparative Study of Ramosetron and Palonosetron in Patients Undergoing Laparoscopic Cholecystectomy - A Prospective Randomized Trial. Anesth Essays Res. 2019 Jan-Mar;13(1):68-72. doi: 10.4103/aer.AER_192_18. PubMed 31031483 ↗
  • Khan MA, Gupta A, Gupta N, Mitra M. Efficacy of Palonosetron and Dexamethasone for Prevention of Post-operative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Cholecystectomy: A Prospective Randomised Double-Blind Trial. Turk J Anaesthesiol Reanim. 2021 Oct;49(5):400-406. doi: 10.5152/TJAR.2021.191. PubMed 35110042 ↗
  • Lal B, Alagarsamy R, Kumar J, Rai AJ, Yadav V, Joshi R, Yunus M. Comparison of efficacy and safety between palonosetron and ondansetron to prevent postoperative nausea and vomiting in patients undergoing non-laparoscopic surgery: A systematic review and meta-analysis of randomised controlled trials. Indian J Anaesth. 2025 Jan;69(1):108-122. doi: 10.4103/ija.ija_1017_24. Epub 2025 Jan 11. PubMed 40046699 ↗
  • Sharma AN, Shankaranarayana P. Postoperative Nausea and Vomiting: Palonosetron with Dexamethasone vs. Ondansetron with Dexamethasone in Laparoscopic Hysterectomies. Oman Med J. 2015 Jul;30(4):252-6. doi: 10.5001/omj.2015.51. PubMed 26366258 ↗
  • Dey S, Chanu SM, Dev P, Borthakur M, Karim HMR, Yunus M. Antiemetic Efficacy of Palonosetron Compared with the Combination of Ondansetron and Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynaecological Surgery. Rom J Anaesth Intensive Care. 2022 Sep 25;28(1):19-24. doi: 10.2478/rjaic-2021-0003. eCollection 2021 Jul. PubMed 36846536 ↗
  • Rajnikant K, Bhukal I, Kaloria N, Soni SL, Kajal K. Comparison of Palonosetron and Dexamethasone with Ondansetron and Dexamethasone to Prevent Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Cholecystectomy. Anesth Essays Res. 2019 Apr-Jun;13(2):317-322. doi: 10.4103/aer.AER_21_19. PubMed 31198253 ↗
  • Xu S, Wang S, Hu S, Ju X, Li Q, Li Y. Effects of lidocaine, dexmedetomidine, and their combination infusion on postoperative nausea and vomiting following laparoscopic hysterectomy: a randomized controlled trial. BMC Anesthesiol. 2021 Aug 4;21(1):199. doi: 10.1186/s12871-021-01420-8. PubMed 34348668 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in May 2026, 8 months.

Of 67 non-industry phase 4 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 67 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Sep 10, 2026
StartActual
Sep 10, 2025
Primary completionActual
May 30, 2026
CompletionActual
May 30, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07813897
Lead sponsor
Bangladesh Medical University
Responsible party
Kazi Mahzabin Arin (AssistantProfessor, Bangladesh Medical University) — Principal investigator
First posted
Sep 10, 2026
Start date
Sep 10, 2025
Primary completion
May 30, 2026
Completion
May 30, 2026
Last update
Sep 10, 2026

Study contacts

AKM Akhtaruzzaman, MD
study director · Bangladesh Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion